Skip to main content

Advertisement

Table 5 Mean change from baseline in CFT at 6 months

From: Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment

Outcome of interest Studies (n) WMD (95% CI) P Study heterogeneity
χ 2 P I 2
IVR 0.5 mg vs non-anti-VEGF       
Type of RVO       
  All trials 4 −216.86 (−279.01, −154.71) <0.001 5.57 0.135 46.1%
  CRVO 2 −230.84 (−357.63, −104.06) <0.001 3.03 0.082 67.0%
  BRVO 2 −190.05 (−243.33, −136.78) <0.001 0.07 0.789 0.00%
Sample size 4 −216.86 (−279.01, −154.71) <0.001 5.57 0.135 46.1%
  >100 2 −233.77 (−328.83, −138.72) <0.001 4.49 0.034 77.7%
  <100 2 −175.95 (−277.40, −74.50) <0.001 0.30 0.585 0.00%
Different non-anti-VEGF treatment       
  All trials 4 −216.86 (−279.01, −154.71) <0.001 5.57 0.135 46.1%
  Sham 3 −216.42 (−292.99, −139.85) <0.001 5.56 0.062 64.0%
  Sham plus laser 1 −210.84 (−371.90, −49.79) <0.001   -  
IVR 0.5 mg vs IVR 0.3 mg 2 −12.26 (−55.60, 31.08) 0.579 0.06 0.812 0.00%
IVR 0.3 mg vs non-anti-VEGF 2 −218.97 (−303.31, −134.63) <0.001 3.39 0.066 70.5%
  1. CFT = central foveal thickness; WMD = weighted mean differences; CI = confidence interval; IVR = intravitreal ranibizumab; VEGF = vascular endothelial growth factor; RVO = retinal vein occlusion; CRVO = central retinal vein occlusion; BRVO = branch retinal vein occlusion.